甲泼尼龙冲击后口服泼尼松与单用口服泼尼松治疗结节病性肾小管间质性肾炎的疗效与安全性:一项随机、开放标签、对照临床试验
这项在法国21个中心开展的多中心、前瞻性、随机、开放标签、对照试验纳入40例经活检证实的结节病所致急性肾小管间质性肾炎患者,比较甲泼尼龙冲击后口服泼尼松(MP组)与单用口服泼尼松(PRD组)。3个月时PRD组20例中16例(80%)达到主要终点,MP组20例中10例(50%)达到(P = .0467);两组3个月中位eGFR无显著差异,严重不良事件无差异。结论认为,与标准口服激素方案相比,静脉甲泼尼龙冲击可能对结节病所致肾小管间质性肾炎患者的肾功能无额外获益。
要点
- 3个月主要终点达成率PRD组80%(16/20) vs MP组50%(10/20),P = .0467。
- 两组3个月中位eGFR无显著差异:PRD组45(IQR 34-74) vs MP组46(IQR 39-65)mL/min/1.73m2。
- 两组严重不良事件无差异,1、3、6、12个月eGFR相似。
核心结论
- 与标准口服激素方案相比,静脉甲泼尼龙冲击可能对结节病所致肾小管间质性肾炎患者的肾功能无额外获益。
研究设计与样本
- 多中心、前瞻性、随机、开放标签、对照试验,在法国21个中心开展,纳入经活检证实的结节病所致急性肾小管间质性肾炎患者。
- 共随机分配40例参与者,MP组接受甲泼尼龙15 mg/kg/天冲击3天后口服泼尼松,PRD组单用口服泼尼松1 mg/kg/天。
- 主要终点为3个月时的阳性反应,定义为估算肾小球滤过率(eGFR)较随机化前翻倍。
主要发现
- 随机化前基线eGFR:PRD组22 mL/min/1.73m2(IQR 16-44),MP组25 mL/min/1.73m2(IQR 22-36),P = .3。
- 两组基线病理病变无差异,包括平均间质纤维化百分比和间质浸润强度。
- 意向治疗人群中,3个月中位eGFR在PRD组为45(IQR 34-74)mL/min/1.73m2,MP组为46(IQR 39-65)mL/min/1.73m2,两组无显著差异。
- 3个月主要终点达成率:PRD组20例中16例(80%),MP组20例中10例(50%),P = .0467。
- 两组治疗1、3、6、12个月后eGFR相似;两组1个月eGFR与12个月eGFR均强相关(P < .0001);两组严重不良事件无差异。
临床怎么用
- 原文结论认为,与标准口服激素方案相比,静脉甲泼尼龙冲击可能对结节病所致肾小管间质性肾炎患者的肾功能无额外获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We determine the benefit of pulsed methylprednisolone for improving kidney function in patients with sarcoidosis tubulointerstitial nephritis. METHODS: We conducted a multicenter, prospective, randomized, open-label, controlled trial in patients with biopsy-proven acute tubulointerstitial nephritis caused by sarcoidosis at 21 sites in France. Patients were randomly assigned to receive a methylprednisolone pulse 15 mg/kg/day for 3 days, then oral prednisone (MP group) or oral prednisone 1 mg/kg/day alone (PRD group). The primary end point was a positive response at 3 months, defined as a doubling of estimated glomerular filtration rate (eGFR) compared with the eGFR before randomization. RESULTS: We randomized 40 participants. Baseline eGFR before PRD was 22 mL/min/1.73m2 {interquartile range [IQR], 16-44} and before MP was 25 mL/min/1.73m2 (IQR, 22-36) (P = .3). The two groups did not differ in underlying pathological lesions, including mean percentage of interstitial fibrosis and intensity of interstitial infiltrate. In the intent-to-treat population, the median eGFR at 3 months did not significantly differ between the PRD and MP groups: 45 (IQR, 34-74) and 46 (IQR, 39-65) mL/min/1.73m2. The primary end point at 3 months was achieved in 16 of 20 (80%) PRD patients and 10 of 20 (50%) MP patients (P = .0467). The eGFR was similar between the two groups after 1, 3, 6, and 12 months of treatment. For both groups, eGFR at 1 month was strongly correlated with eGFR at 12 months (P < .0001). The two groups did not differ in severe adverse events. CONCLUSION: Compared with a standard oral steroid regimen, intravenous MP may have no supplemental benefit for renal function in patients with tubulointerstitial nephritis caused by sarcoidosis.Trial Registration: ClinicalTrials.gov: NCT01652417; EudraCT: 2012-000149-11.
引用
- Mahevas M, Audard V, Rousseau A, et al. Efficacy and safety of methylprednisolone pulse followed by oral prednisone vs. oral prednisone alone in sarcoidosis tubulointerstitial nephritis: a randomized, open-label, controlled clinical trial. Nephrol Dial Transplant. 2023. PMID: 36066903. doi:10.1093/ndt/gfac227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。